> top > docs > PubMed:10089214

PubMed:10089214 JSONTXT

Differential expression of alpha2-6 sialylated polylactosamine structures by human B and T cells. We found that human peripheral B and T cells differed in the surface expression of alpha2-6 sialylated type 2 chain glycans. In contrast to B cells, T cells expressed only sialoglycans with repeated N-acetyllactosamine (Galss1-4GlcNAc) disaccharides. This finding was based on the specificity of the monoclonal antibodies HB6, HB9 (CD24), HD66 (CDw76), FB21, and CRIS4 (CDw76) with the alpha2-6 sialylated model gangliosides IV6NeuAcnLc4Cer (2-6 SPG), VI6NeuAcnLc6Cer (2-6 SnHC), VIII6NeuAcnLc8Cer (2-6 SnOC), and X6NeuAcnLc10Cer (2-6 SnDC). We found that, in addition to their common requirement of an alpha2-6 bound terminal sialic acid for binding, the antibodies displayed preferences for the length of the carbohydrate backbones. Some of them bound mainly to 2-6 SPG with one N-acetyllactosamine (LacNAc) unit (HB9, HD66); others preferentially to 2-6 SnHC and 2-6 SnOC, with two and three LacNAc units, respectively (HB6 and FB21); and one of them exclusively to very polar alpha2-6 sialylated type 2 chain antigens (CRIS4) such as to 2-6 SnOC and even more polar gangliosides with three and more LacNAc units. These specificities could be correlated with the cellular binding of the antibodies as follows: whereas all antibodies bound to human CD 19 positive peripheral B cells, their reactivity with CD3 positive T cells was either nearly lacking (HD66, HB9), intermediate (about 65%: HB6, FB21) or strongly positive (CRIS4, 95%). Thus, the binding of the antibodies to 2-6 sialylated glycans with multiple lactosamine units appeared to determine their binding to T-cells.

projects that include this document

Unselected / annnotation Selected / annnotation
Glycan-Motif 4 (4) glycosmos_glycans 0 (0) GlyCosmos600-GlycoGene3 0 (0) GlyCosmos600-GlycoGenes2 0 (0) GlyCosmos600-Glycan-Motif-Structure 4 (4) GlyCosmos6-Glycan-Motif-Image 4 (4) GlyCosmos6-docs 0 (0) Glycosmos6-GlycoEpitope 0 (0) GlyCosmos6-Glycan-Motif-Structure 4 (4) Glycosmos6-MAT 0 (0) sentences 16 (16) GlycoBiology-GDGDB 0 (0) GlycoBiology-cGGDB 0 (0) GlycoBiology-PACDB 0 (0) GlycoBiology-GO 0 (0) ICD10 0 (0) GlycoBiology-FMA 46 (46) uniprot-human 6 (6) uniprot-mouse 1 (1) GlycoBiology-NCBITAXON 9 (9) GO-BP 9 (9) GO-MF 22 (22) GO-CC 7 (7) UBERON-AE 0 (0) EDAM-topics 6 (6) EDAM-DFO 3 (3) GlyCosmos600-FMA 12 (12) GlyCosmos600-CLO 10 (10) GlycoBiology-MAT 0 (0) GlyCosmos-GlycanStructure-c 0 (0) glycoprotein 0 (0) GlyCosmos600-GlycanStructure 0 (0) GlyCosmos600-GlycoGenes 0 (0) glycosmos-test-glycan-structure 4 (4) GlyCosmos600-docs 0 (0) glycosmos-test-structure-v1 4 (4) GlyCosmos600-MAT 0 (0) GlyCosmos600-GlycoProteins 0 (0) GlyCosmos600-GlycoEpitope 0 (0) Glycan-Abbreviation 0 (0) pubmed-enju-pas 306 (306) performance-test 0 (0) glytoucan-iupac 0 (0) GlycoBiology-Motifs 2 (2) Lectin 0 (0) acggdb_ggdb 0 (0) GlycoBiology-Epitope 0 (0) GlyTouCan-IUPAC 98 (98) GlyCosmos15-Glycan 3 (3) mondo_disease 1 (1) Anatomy-MAT 0 (0) HP-phenotype 0 (0) Glycan-GlyCosmos 3 (3) GlyCosmos15-HP 0 (0) GlyCosmos15-CL 7 (7) GlyCosmos15-UBERON 1 (1) GlyCosmos15-Taxon 3 (3) GlyCosmos15-Sentences 0 (0) GlyCosmos15-GlycoEpitope 0 (0) GlyCosmos15-Lectin-Jamboree 0 (0) Lectin-Jamboree 0 (0) GlyCosmos15-MONDO 0 (0) GlyCosmos15-FMA 1 (1) GlyCosmos15-MAT 0 (0) NCBITAXON 3 (3) GlyCosmos-GlycoEpitope 0 (0) Anatomy-UBERON 1 (1) GlyCosmos15-Lectin 0 (0) Lectin_test 0 (0) CL-cell 7 (7) GlyCosmos15-docs 0 (0)